Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine granules for prevention of recurrence of diverticulitis
2009-015158-39Phase 3Terminated
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in diverticulitis (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Proportion of recurrence-free patients at 48 weeks. Started Mar 2010; status: terminated.
02
Drugs
Salcrozine
03
Conditions
diverticulitis
Beyond the preview
Go deeper on 2009-015158-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015158-39.